<DOC>
	<DOCNO>NCT02788409</DOCNO>
	<brief_summary>This study conduct estimate population-based incidence rate second primary malignancy among patient CRPC similar treat Xofigo . These rate provide context second primary malignancy incidence rate REASSURE study . Furthermore study aim provide information documentation bone metastases Medicare data extent use oral androgen deprivation drug among patient Medicare Part D coverage , well estimate overall survival study population .</brief_summary>
	<brief_title>Incidence Second Primary Malignancies Castration-Resistant Prostate Cancer : An Observational Retrospective Cohort Study US</brief_title>
	<detailed_description>Xofigo ( radium-223 dichloride ) alpha-emitting pharmaceutical , approve treatment patient castration-resistant prostate cancer ( CRPC ) , symptomatic bone metastasis , know visceral metastatic disease . The long-term safety profile Xofigo evaluate prospective REASSURE study , estimate incidence rate second primary malignancy patient CRPC receive Xofigo . To provide context , retrospective study conduct estimate background rate second primary malignancy among patient CRPC similar treat Xofigo .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<criteria>Enrolled Medicare Parts A B least 1 year cohort entry date ( minimum lookback period comorbidities treatment ) Primary site code prostate cancer ( International Classification Diseases Oncology , Third Edition [ ICDO3 ] topography code C61.9 ) SEER data Surgical castration androgen deprivation therapy prostate cancer diagnosis ; androgen deprivation therapy indicate use follow drug : abarelix , bicalutamide , buserelin , cyproterone , degarelix , diethylstilbestrol , estramustine , flutamide , gonadorelin , goserelin , histrelin , leuprolide , medroxyprogesterone , megestrol , nafarelin , nilutamide , polyestradiol , triptorelin Evidence prostate cancer resistant surgical castration androgen deprivation therapy ( `` castrationresistant prostate cancer '' ) , indicate start one follow secondline systemic therapy ( cohort entry date ) : abiraterone , cabazitaxel , docetaxel , enzalutamide , mitoxantrone , sipuleucelT Cohort entry date 01 January 2006 later Age 65 year old US cohort entry date Enrollment HMO ( Health Maintenance Organization ) year cohort entry date Diagnosis cancer prostate cancer nonmelanoma skin cancer cohort entry date Any diagnostic code metastases bone metastasis lymph node metastasis cohort entry date Any claim treatment Xofigo cohort entry date .</criteria>
	<gender>Male</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>